NASDAQ · Biotechnology

ROIV (ROIV) Stock

$34.41 +0.67% NASDAQ: ROIV Healthcare

Valuation

MetricValue
Price$34.41
Market Cap$24.86B
P/E Ratio-93.84
P/B Ratio6.07
P/S Ratio3420.21
EPS (TTM)$-0.24
52-Week High$37.97
52-Week Low$11.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.12%
ROA-5.02%
ROCE-27.20%
Gross Margin-3458.62%
Operating Margin-3458.62%
Net Margin-60.80%
Debt/Equity0.03
Current Ratio33.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$55.0M$32.0M$33.0M$29.0M$8.0M
Operating Profit$-1.2B$-809.0M$-825.0M$-1.1B$-1.3B
Net Profit$-845.0M$-1.0B$4.3B$-172.0M$-300.0M
EPS$-1.26$-1.42$5.23$-0.24$-0.43
Op Margin-2191.8%-2565.8%-2521.7%-3833.3%-15560.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.6B$2.4B$7.2B$5.4B$5.7B
Total Liabilities$524.0M$782.0M$774.0M$250.0M$436.0M
Cash$2.1B$1.7B$6.5B$2.7B$1.4B
Borrowings$284.0M$481.0M$500.0M$100.0M$107.0M

Latest News

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents MT Newswires · Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders GlobeNewswire · Jul 16, 2026 ROIV: Lowering target price to $37.00 Argus Research · Jul 15, 2026 ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week Stocktwits · Jul 7, 2026 Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? Motley Fool · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-678.0M$-843.0M$-765.0M$-839.0M$-750.0M
Investing Cash Flow$286.0M$-57.0M$5.2B$-1.8B$-691.0M
Financing Cash Flow$192.0M$-10.0M$18.0M$-1.3B$-329.0M
Net Cash Flow$-68.0M$-382.0M$4.9B$-3.8B$-1.3B
Free Cash Flow$-695.0M$-856.0M$-767.0M$-844.0M$-759.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.78
EV / EBITDA-87.51
FCF Yield-3.16%
Quick Ratio16.72
Interest Coverage0.00
Return 1Y175.87%
Return 3Y192.64%
Return 5Y243.17%

Ownership

Insiders Held23.39%
Institutions Held76.19%
Institutions Float Held99.44%
Institutional HolderSharesReport Date
FMR, LLC77,981,2532026-03-31
Morgan Stanley51,828,3252026-03-31
Blackrock Inc.44,254,2602026-03-31
QVT Financial LP25,161,2372026-03-31
UBS Group AG22,619,4722026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASND $271.12 +1.43% 25.59 $16.84B 0.00%
BBIO $75.41 -1.42% -21.37 $14.77B 0.00%
EXASExact Sciences Corporation $104.91 — -95.37 $20.03B 0.00%
IONS $58.13 -5.22% -41.80 $9.66B 0.00%
JAZZ $247.57 +0.81% 16.57 $15.55B 0.00%

About ROIV

ROIV is led by CEO Matthew Gline, employs 721 people, headquartered in London, GB, publicly traded since 2020.

ROIV stock trades at $34.41 with a market capitalization of $24.86B. The stock is valued at a price-to-earnings (P/E) ratio of -93.84, price-to-book of 6.07, price-to-sales of 3420.21. Over the past 52 weeks the stock has ranged between $11.85 and $37.97, and currently trades 9.4% below its 52-week high.

On profitability, ROIV generates a return on equity (ROE) of -6.12%, return on capital employed of -27.20%, an operating margin of -3458.62%, a net profit margin of -60.80%.

In its most recent fiscal year, ROIV reported annual revenue of $8.0M, net profit of $-300.0M, revenue has compounded at -19.7% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.03 — a conservative balance sheet with little leverage risk, a current ratio of 33.56, total assets of $5.7B, $1.4B in cash and equivalents.

ROIV has a beta of 1.13.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1149.22 -0.89% JNJ Drug Manufacturers - General $276.92 -0.54% ABBV Drug Manufacturers - General $258.59 -0.62% MRK Drug Manufacturers - General $151.41 -0.61% UNH Medical - Healthcare Plans $400.78 -0.04% NVS Drug Manufacturers - General $160.60 -1.53% AZN Drug Manufacturers - General $163.51 -0.76% AMGN Drug Manufacturers - General $440.55 -0.80% TMO Medical - Diagnostics & Research $611.83 -1.07% NVO Biotechnology $47.51 +1.58% ABT Medical - Devices $108.70 -0.08% GILD Drug Manufacturers - General $150.89 -0.22%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides